← Leaderboards
Todd Anthony Miano
University Of Pennsylvania
$1,966,415
Attributed
$1,966,415
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,966,415 · 4
By mechanism
R01$804,993 · 1
K08$790,720 · 1
R21$243,750 · 1
F32$126,952 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Kathryn Helene Bowles$16,286,736
- Stephen R Master$432,518
- Daniel Benjamin Horton$8,748,567
- Elaine Sang$95,717
- Haedi Thelen$83,884
Others in their field
Top investigators on “Hospitalization”
- Larry Arthur$288,323,000
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$230,275,254
- Judith S. Currier · University Of California Los Angeles$223,149,861
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$221,207,102
- Lawrence Corey · Fred Hutchinson Cancer Center$217,829,567
- Daniel R Kuritzkes · Brigham And Women'S Hospital$179,610,394
Research focus
HospitalizationPharmaceutical PreparationsAcuteRenal FunctionInjuryResearch PersonnelPreventSepsisMediatingHospitalsInvestigationPrevention StrategyCohort StudiesDrug KineticsLifeFosteringDatabasesInsightDesignFutureLeadInfectionPharmacoepidemiologySkills
Grant awards (9)
Markers of Nephrotoxicity during treatment with Antibiotic Combinations: The MONACO clinical trial$804,993
R01 · FY2025 · DK · contact PI
Renin as a Predictive and Prognostic Biomarker in Sepsis-Induced Hypotension$243,750
R21 · FY2025 · HL · contact PI
Drug-drug interactions and kidney disease in hospitalized patients$157,956
K08 · FY2025 · DK · contact PI
Drug-drug interactions and kidney disease in hospitalized patients$157,956
K08 · FY2024 · DK · contact PI
Drug-drug interactions and kidney disease in hospitalized patients$157,956
K08 · FY2023 · DK · contact PI
Drug-drug interactions and kidney disease in hospitalized patients$157,956
K08 · FY2022 · DK · contact PI
Drug-drug interactions and kidney disease in hospitalized patients$158,896
K08 · FY2021 · DK · contact PI
Comparative Effectiveness of Enoxaparin vs. Dalteparin for Thromboprophylaxis Aft$59,330
F32 · FY2015 · HL · contact PI
Comparative Effectiveness of Enoxaparin vs. Dalteparin for Thromboprophylaxis Aft$67,622
F32 · FY2014 · HL · contact PI